Erratum: Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease (Blood Advances (2017) 1:20 (1645-1649) DOI: 10.1182/bloodadvances.2017009613)

J. J. Field, E. Majerus, V. R. Gordeuk

Research output: Contribution to journalComment/debate

Abstract

In the "Acknowledgments" section on page 1648 of the 12 September 2017 issue, an acknowledgment of support from Charles T. Quinn, Jeffrey Keefer, Paul Swerdlow, and Marilyn Telen was missing. Also, the author initials associated with grants R01 HL098526 and P50HL110790 should have been excluded, because the grants funded more individuals than originally indicated. The errors have been corrected in the published article.

Original languageEnglish
Number of pages1
JournalBlood Advances
Volume1
Issue number23
DOIs
StatePublished - Oct 24 2017
Externally publishedYes

Fingerprint Dive into the research topics of 'Erratum: Randomized phase 2 trial of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease (Blood Advances (2017) 1:20 (1645-1649) DOI: 10.1182/bloodadvances.2017009613)'. Together they form a unique fingerprint.

  • Cite this